Your browser doesn't support javascript.
loading
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
Tewari, Krishnansu S; Colombo, Nicoletta; Monk, Bradley J; Dubot, Coraline; Cáceres, M Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Salman, Pamela; Yañez, Eduardo; Gümüs, Mahmut; Olivera Hurtado de Mendoza, Mivael; Samouëlian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Tekin, Cumhur; Li, Kan; Toker, Sarper; Keefe, Stephen M; Lorusso, Domenica.
Affiliation
  • Tewari KS; Obstetrics & Gynecology, University of California, Irvine, Orange.
  • Colombo N; Gynecologic Oncology, European Institute of Oncology IRCCS and Università degli Studi di Milano Bicocca, Milan, Italy.
  • Monk BJ; HonorHealth Research Institute, University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix.
  • Dubot C; Oncologie Médicale, Institut Curie Saint Cloud, and GINECO, Paris, France.
  • Cáceres MV; Medical Oncology, Instituto de Oncologia Angel H. Roffo, Buenos Aires, Argentina.
  • Hasegawa K; Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Shapira-Frommer R; Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Salman P; Medical Oncology, Oncovida Cancer Center, Providencia, Santiago, Chile.
  • Yañez E; Medical Oncology, Universidad de la Frontera, Temuco, Chile.
  • Gümüs M; Medical Oncology, Istanbul Medeniyet University Hospital, Istanbul, Turkey.
  • Olivera Hurtado de Mendoza M; Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Samouëlian V; Gynecologic Oncology, Centre Hospitalier de l'Université de Montréal, Centre de Recherche de l'Université de Montréal, Université de Montréal, Montreal, Quebec, Canada.
  • Castonguay V; Medical Oncology, Centre Hospitalier Universitaire de Québec, Université Laval, Quebec City, Quebec, Canada.
  • Arkhipov A; Oncology and Chemical Therapy, Medical Rehabilitation Center Under the Ministry of Health of Russian Federation, Moscow, Russian Federation.
  • Tekin C; Oncology, Merck & Co, Inc, Rahway, New Jersey.
  • Li K; Oncology, Merck & Co, Inc, Rahway, New Jersey.
  • Toker S; Oncology, Merck & Co, Inc, Rahway, New Jersey.
  • Keefe SM; Oncology, Merck & Co, Inc, Rahway, New Jersey.
  • Lorusso D; Gynaecology Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
JAMA Oncol ; 10(2): 185-192, 2024 Feb 01.
Article in En | MEDLINE | ID: mdl-38095881
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Uterine Cervical Neoplasms / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: JAMA Oncol Year: 2024 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Uterine Cervical Neoplasms / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: JAMA Oncol Year: 2024 Document type: Article Country of publication: Estados Unidos